Orbita uses Amazon Echo for home health solution
BOSTON – Orbita, a provider of software solutions for connected home healthcare, has launched a tool for creating and managing intelligent voice-powered home health assistants based on the Amazon Echo voice platform. The company’s Voice Experience Designer is a graphical tool for creating and managing voice assistants to support and enhance the care of individuals at home. With the Orbita solution, healthcare providers can easily build and deploy voice-powered applications for a variety of home health scenarios, including treatment and medication adherence, caregiver coordination, pain management and patient monitoring. Bill Rogers, Orbita founder and CEO, said devices like the Amazon Echo have changed how people perceive and use voice assistants. “Instead of requiring someone to speak into a smartphone, the Echo offers an array of sensitive microphones and a built-in speaker,” Rogers said. “It’s ‘always on/always listening’ capabilities bring powerful advantages to home care needs.”
Verily Life Sciences launches smart utensil
SAN FRANCISCO – Verily Life Sciences (formerly Google Life Sciences) has launched the Liftware Level, a smart utensil designed to help individuals with limited hand and arm mobility hold a fork or spoon at the angle needed to feed themselves. “Designed and developed with significant input from physicians and potential users, we hope this new device will turn the everyday task of eating into a more pleasurable experience for more people living with movement disorders,” said Anupam Pathak, creator of Liftware and technical lead at Verily. The Liftware Level handle, combined with a spoon or fork attachment, is able to recognize the position of the hand at all times and intelligently adjusts the angle of the utensil so users can eat without fear of spilling. Liftware Level is the second product in the Liftware family. The Liftware Steady is a computerized stabilizing handle and a selection of similarly utensil attachments designed to counteract the effects of hand tremors.
Nanowear receives green light from FDA for cardiac monitoring undergarment
NEW YORK - Nanowear has received clearance from the U.S. Food and Drug Administration for a remote cardiac monitoring undergarment called SimplECG. “The FDA’s decision not only positions us for commercial opportunities in remote cardiac monitoring, but more importantly, it provides accreditation of the company’s one-of-a-kind, cloth-based sensor technology as medical-grade,” said Venk Varadan, Nanowear CEO and co-founder, in a statement. This is the first step and foundation of what the company believes to be an extensive array of applications for its nanosensor technology, including numerous other electrical, biometric and biochemical signals that can be measured directly from the skin without conductive gels, adhesives or skin preparation. “The market of applications for healthcare alone is a multi-billion-dollar opportunity, but as we look beyond to consumer, industrial, clinical research, military and public sector applications, the addressable market expands exponentially,” said Varadan. Having spent the last two years focused solely on product development and the regulatory process, Nanowear will now focus its near-term efforts on product commercialization, strategic partnerships and continued development of complementary products and applications for chronic disease states.
Sunovion incorporates digital health technologies
MARLBOROUGH, Mass – Sunovion Pharmaceuticals will conduct a Phase 4 clinical study of the seizure-reducing drug Aptiom using the Embrace watch by Empatica. “We believe that incorporating digital health technologies into traditional treatment paradigms has the potential to inform and enhance best practices and further empower people living with serious medical conditions and their families,” said Dr. Antony Loebel, Sunovion’s executive vice president and chief medical officer, in a statement. The watch will be used to detect and record partial-onset seizures subjectively identified by patients or caregivers—the first time that a wearable seizure detection device has been incorporated into the trial design of an anti-epileptic drug for partial-onset seizures such as Aptiom. The study will enroll approximately 190 adults with partial-onset seizures, and will evaluate the impact on seizure frequency, safety, mood and quality of life measures.
Livongo meter updates now downloadable
MOUNTAIN VIEW, Calif. – Patients using the Livongo glucose meter can now download software updates for the device, a first in the market, said the company. The ability to download “creates the possibility to give people a meter that is designed for their needs—making it easier for people to stay healthy,” said Glen Tullman, Livongo CEO, in a statement. “And that’s what we want—to empower people with chronic conditions to manage their diseases and to live the lives they want.” The Livongo meter automatically uploads blood glucose data and can now download software updates and feature enhancement.